Pre-made Girentuximab benchmark antibody ( Whole mAb Radiolabelled, anti-CA9/CA-IX therapeutic antibody, Anti-CAIX/MN Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Girentuximab biosimilar, Whole mAb Radiolabelled, Anti-CA9/CA-IX Antibody: Anti-CAIX/MN therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Girentuximab (trade name Rencarex) is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX).[1] CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. It is investigational agent in clinical trials for renal cell carcinoma. Its development was suspended as a “naked” or unconjugated antibody during phase III trials due to efficacy.
| Products Name (INN Index) | Pre-Made Girentuximab biosimilar, Whole mAb Radiolabelled, Anti-CA9/CA-IX Antibody: Anti-CAIX/MN therapeutic antibody |
|---|---|
| INN Name | Girentuximab |
| Target | CA9 |
| Format | Whole mAb Radiolabelled |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2009 |
| Year Recommended | 2010 |
| Companies | Centocor Inc,Heidelberg Pharma AG |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Renal cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CA9 |
| Package |
